Institut Curie Announces formation of Honing Biosciences for the Development of Cell Therapies in Cancer and Chronic Diseases
Shots:
- Honing Biosciences will use CellTune molecular technology- that will initially emphasize on cancer immunotherapies particularly the CAR-T cells to target cancer cells
- The focus on this launch is to provide long-term care for cancer patients using a single injection of therapeutic cells- with the development of safe- effective and affordable approaches
- CellTune molecular technology monitors the dynamic distribution of proteins in cell-medicaments that will further help in developing new class of cell therapies
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
